Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Recurrent cervical cancer.

Mario M Leitao1, Dennis S Chi

  • 1Memorial Sloan-Kettering Cancer Center, Gynecology Service, Department of Surgery, c/o Gynecology Service Academic Office, 1275 York Avenue, Room MRI-1027, New York, NY 10021, USA. gynbreast@mskcc.org

Current Treatment Options in Oncology
|June 12, 2002
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Preoperative hypoalbuminemia and survival among patients selected for primary cytoreduction in advanced ovarian cancer: A Memorial Sloan Kettering Cancer Center Team Ovary study.

Gynecologic oncology·2026
Same author

Successful bilateral sentinel lymph node mapping rate and empty nodal packet rate in uterine cancer.

International journal of gynecological cancer : official journal of the International Gynecological Cancer Society·2026
Same author

Liver resection at the time of secondary cytoreduction in ovarian cancer.

Gynecologic oncology reports·2026
Same author

Noncompete agreements in job contracts: Knowledge and opinion of practicing gynecologic oncologist members of Society of Gynecologic Oncology.

Gynecologic oncology·2026
Same author

Assessing the clinical value of pre-operative imaging in endometrial carcinoma by symptoms and low-risk versus high-risk histology.

International journal of gynecological cancer : official journal of the International Gynecological Cancer Society·2026
Same author

Sensitive CAR T cells redefine targetable CD70 expression in solid tumors.

Science (New York, N.Y.)·2026
Same journal

Interaction between Regulated Cell Death Pathways and Core Cellular Processes: Unraveling the Molecular Mechanisms of Cardiotoxicity of Antitumor Drugs.

Current treatment options in oncology·2026
Same journal

Advances in Immunotherapy for Breast Cancer: Up-to-date Strategies of Immune Checkpoint Inhibitors and Therapeutic Vaccines.

Current treatment options in oncology·2026
Same journal

Recent Advances in Neoadjuvant Treatment of Anaplastic Thyroid Carcinoma: A Narrative Review.

Current treatment options in oncology·2026
Same journal

The Immunological Landscape of the Tumor Microenvironment: Implications for Immunotherapy of Unresectable and Metastatic Soft Tissue Sarcomas.

Current treatment options in oncology·2026
Same journal

Oncofertility in the Age of HER2 Blockade, Immunotherapy, PARP inhibitors, CDK4/6 inhibitors and Endocrine Treatment: Unanswered Questions in Breast Cancer.

Current treatment options in oncology·2026
Same journal

Emerging Applications of CAR-T Cell Therapy in Overcoming Resistance and Expanding Targets in Hematologic Malignancies: Insights from Recent Research.

Current treatment options in oncology·2026
See all related articles

Treatment options for recurrent cervical cancer are limited. Pelvic exenteration or radical surgery with high-dose-rate intraoperative radiation therapy (HDR-IORT) offers the best chance for long-term survival in select patients.

Area of Science:

  • Gynecologic Oncology
  • Radiation Oncology
  • Surgical Oncology

Background:

  • Limited effective treatment options exist for recurrent cervical carcinoma.
  • Chemotherapy and standard radiation therapy often provide only palliative benefits for unresectable or previously irradiated recurrent disease.
  • Salvage radiation therapy or surgical resection are considered for specific patient groups.

Purpose of the Study:

  • To review treatment strategies for recurrent cervical carcinoma.
  • To identify patient populations who may benefit from advanced surgical and radiation techniques.
  • To highlight the role of pelvic exenteration and HDR-IORT in managing recurrent cervical cancer.

Main Methods:

  • Review of current treatment paradigms for recurrent cervical cancer.

Related Experiment Videos

  • Discussion of criteria for surgical resection, including radical hysterectomy and pelvic exenteration.
  • Evaluation of the impact of high-dose-rate intraoperative radiation therapy (HDR-IORT) in combination with radical surgery.

    • Main Results:

    • Pelvic exenteration is the primary option for long-term survival in central local recurrences without pelvic sidewall extension.
    • Radical hysterectomy is feasible for very rare, small, centrally located recurrences.
    • HDR-IORT combined with radical surgery expands surgical candidacy for patients with recurrent cervical cancer, including those previously irradiated.

    Conclusions:

    • For surgically fit patients with centrally located recurrences after prior radiation, surgical resection should be considered.
    • Patients with recurrences near the pelvic sidewalls should be referred to centers with HDR-IORT expertise.
    • Advanced treatment modalities like HDR-IORT are crucial for improving outcomes in recurrent cervical cancer.